Betta Pharmaceuticals Co.,Ltd
Research Betta Pharmaceuticals Co.,Ltd (300558.SZ) on Bullrun: market cap CNY 19.52B, P/E 73.2, dividend yield 0.3%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker300558.SZ
- ExchangeSZ
- CountryChina
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyCNY
- Market capCNY 19.52B
- P/E73.2
- Dividend yield0.3%
- Financial periodQ2 2026
- RevenueCNY 936.09M
- Net incomeCNY 66.22M
- Free cash flowCNY 114.75M
- Gross margin73.5%
Valuation Snapshot
latest market cap is CNY 19.52B; P/E is 73.2; dividend yield is 0.3%.
Peer valuation comparison
Latest P/E is 73.21x versus a Healthcare sector median of 21.8x (235.9% above).
Latest dividend yield is 0.32% versus a Healthcare sector median of 2.4% (86.7% below).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-11-11 | CNY 19.52B | 73.2 | 0.3% | 0.15 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.15 CNY, yield 0.3%.
About Betta Pharmaceuticals Co.,Ltd
Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China and internationally. The company offers Icotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat first-line treatment of locally advanced or non-small-cell lung cancer (NSCLC); Ensartinib hydrochloride, an anaplastic lymphoma kinase inhibitor for the treatment of NSCLC;
ETFs that hold Betta Pharmaceuticals Co.,Ltd
US-listed ETFs
Betta Pharmaceuticals Co.,Ltd is held by 15 US-listed ETFs, going by the latest portfolios they filed with the SEC. The 8 most traded of them:
| ETF | Weight | Fee |
|---|---|---|
| Vanguard Total International Stock Index Fund ETF Shares (VXUS) | <0.01% | 0.05% |
| Vanguard FTSE Emerging Markets Index Fund ETF Shares (VWO) | <0.01% | 0.06% |
| Vanguard Total World Stock Index Fund ETF Shares (VT) | <0.01% | 0.06% |
| Vanguard FTSE All-World ex-US Index Fund ETF Shares (VEU) | <0.01% | 0.04% |
| Schwab Emerging Markets Equity ETF (SCHE) | <0.01% | 0.06% |
| Dimensional Emerging Core Equity Market ETF (DFAE) | <0.01% | 0.29% |
| Dimensional Emerging Markets Core Equity 2 ETF (DFEM) | <0.01% | 0.39% |
| Dimensional World ex U.S. Core Equity 2 ETF (DFAX) | <0.01% | 0.28% |
Portfolios as filed with the SEC on Form N-PORT, dated May to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Betta Pharmaceuticals Co.,Ltd's market cap?
Betta Pharmaceuticals Co.,Ltd's market capitalization is CNY 19.52B.
What is Betta Pharmaceuticals Co.,Ltd's P/E ratio?
Betta Pharmaceuticals Co.,Ltd's price-to-earnings (P/E) ratio is 73.2.
Does Betta Pharmaceuticals Co.,Ltd pay a dividend?
Betta Pharmaceuticals Co.,Ltd has a dividend yield of 0.3%.
What does Betta Pharmaceuticals Co.,Ltd do?
Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China and internationally.